COCHW · Envoy Medical, Inc.

The appointment of Charles S. McKhann to Envoy Medical’s Board of Directors represents a deliberate governance enhancement, bringing deep medical device leadership experience—including prior CEO roles at Silk Road Medical and Apollo Endosurgery, both acquired by Boston Scientific—as well as current board service at Exagen, Inc. and executive chairmanship at Distalmotion SA. His placement on the Compensation Committee is notable given the Board’s explicit determination of his independence under Nasdaq and SEC standards, including enhanced criteria for compensation committee members. The expansion of the Board from six to seven members signals intentional capacity building rather than reactive adjustment. The 100,000-share option grant—priced at $0.72 per share with ratable 36-month vesting—establishes immediate alignment with long-term shareholder value creation without upfront cash compensation. While no financial or operational metrics are disclosed in this filing, the addition of a seasoned, independent director with proven commercial and strategic execution in adjacent medtech subsectors may support future capital allocation decisions, regulatory strategy, and potential M&A readiness—factors investors will assess in context of Envoy’s growth stage and cochlear implant market positioning.